Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease
that is considered to be the most common liver disease all over the world. It causes metabolic and
hepatic damage that can progress to cirrhosis and hepatocellular carcinoma.
Objective: Our research pointed to study the preventive effects of Canagliflozin (CANA) in
comparison with Atorvastatin (ATO) as well as the combination of both on the development of
experimental hepatic steatosis and dyslipidemia.
Methods: Animals were grouped as control group; Dexamethasone (DEX) group; ATO/DEX
treated group; CANA/DEX treated group and ATO+CANA/DEX treated group.
Results: Significant elevations were observed in GSH, SOD and CAT activities, while highly significant
decreases were observed in serum GOT, GPT, ALP, urea, blood glucose, CK-MB, LDH,
T.G, T.C, MDA and P.C levels in the treated groups as compared to DEX group during experimental
periods. Also, significant reductions in SGPT, SGOT, ALP, CK-MB, LDH, T.C and T.G levels
were observed in CANA/DEX group as compared to ATO/DEX group. All these results were confirmed
with histopathological findings where the severe damages and fatty degeneration in both
kidney and liver tissues that developed by DEX administration were resolved by administration of
ATO alone or in combination with CANA.
Conclusion: These results indicate that CANA was as effective as ATO or a combination of both in
reducing dyslipidemia and hepatic steatosis. The antioxidant and hypolipidemic effects of CANA
may be responsible for the beneficial effects.